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Abstract
Coronavirus disease 2019 (COVID-19) was first officially described in Brazil on February 26th, 2020. The accumulation of reports of 
concomitant infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pathogens that cause diseases endemic 
to tropical countries, such as dengue and chikungunya fever, has started to draw attention. Chagas disease and leprosy remain public 
health problems in many developing countries, such as Brazil. In this manuscript, we describe a case of concomitant leprosy, Chagas 
disease, and COVID-19, highlighting the cutaneous manifestations of SARS-CoV-2 infection and the clinical behavior of household 
contacts who previously received prophylactic Bacillus Calmette-Guérin vaccines.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) was first officially 
described in São Paulo, Brazil on February 26th, 2020, and since 
then, the country has experienced a concerning increase in the 
incidence of COVID-19. As of June 10th, 2020, 772,416 positive 
cases had been identified, with 39,680 deaths1. The growing 
number of reports of concomitant infections with SARS-CoV-2 and 
pathogens that cause diseases endemic to tropical countries, such 
as dengue and chikungunya fever, has drawn attention2. Chagas 
disease and leprosy continue to remain public health problems in 
many developing countries, including Brazil3. In this manuscript, we 
describe a case of concomitant leprosy, chronic Chagas disease, and 
COVID-19, highlighting the cutaneous manifestations of SARS-
CoV-2 infection and the clinical behavior of household contacts 
who had previously received prophylactic Bacillus Calmette-Guérin 
(BCG) vaccines. Patient inclusion was approved by the Ethics 
Committee of the Faculty of Medicine of Universidade de Brasília 
after informed consent was obtained (95411718.2.0000.0030).
CASE REPORT
The patient, a 43-year-old female resident of Paranoá, in 
the Federal District of midwestern Brazil, was diagnosed with 
dimorphic leprosy in 2010 via positive smear microscopy and 
the presence of asymmetric multiple mononeuritis. She started 
treatment with multibacillary multidrug therapy (MDT-MB) in 
August 2010. However, she experienced multiple interruptions in 
treatment due to adverse reactions, until the therapy was finally 
terminated in April 2020 after the administration of dapsone caused 
hemolytic anemia. She was also diagnosed with Chagas disease 
in 2013 via serology (chemiluminescence), and because she had 
cardiac involvement and arrhythmia, she required a pacemaker 
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FIGURE 1: Ulcerated vulvar lesion.
as well as treatment with propranolol (80 mg/day) and Marevan 
(5 mg/day). The patient was scheduled to start a monthly treatment 
regimen with rifampicin, ofloxacin, and minocycline. However, she 
returned in May 2020 with complaints of fatigue, odynophagia, 
anosmia, ageusia, and headache for the prior 3 days. Reverse 
transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 
was performed from a nasopharyngeal swab sample, and the result 
was positive. Her condition progressed, and she developed diarrhea 
and rectal bleeding in addition to cheilitis and painful, ulcerated 
lesions on her genital (Figure 1) and oral mucosae; however, the 
patient did  not experience worsening of her leprosy symptoms, 
nor did she develop reactional states. No fever or respiratory 
symptoms were observed. The patient lived with her husband, who 
was also using MDT-MB treatment for leprosy, and her daughter, 
who had received BCG vaccine chemoprophylaxis in January 
2020. Although her husband and daughter were classified as close 
household contacts, neither presented with symptoms, nor did they 
test positive for SARS-CoV-2 using RT-PCR or anti-SARS-CoV-2 
antibodies using serology.
DISCUSSION
Leprosy is a chronic, infectious, granulomatous disease 
that affects the skin and peripheral nerves and is caused by 
Mycobacterium leprae and Mycobacterium lepromatosis. The 
majority (90%) of current leprosy cases are found in Brazil, India, 
Nepal, Myanmar, Madagascar, and Mozambique, and 80% of the 
cases that occur in the Americas are concentrated in Brazil4. There 
are no current data regarding cases of concomitant COVID-19 
and leprosy. However, information about the possible effects of 
these concomitant diseases and the effects of the drugs used for 
the treatment of either COVID-19 or leprosy may be important. 
Another important focus is the possible increase of the frequency 
and intensity of the reactional state, as would be expected in cases 
in which leprosy patients contract other viral infections5. Leprosy 
reactions are characterized by malaise and the exacerbation of 
preexisting lesions, with subsequent erythema and pain that 
are usually accompanied by neuritis and severe edema of the 
extremities, occurring in 40% of borderline lepromatous patients5.
In the present case, the patient was in the chronic phase of Chagas 
disease, characterized by congestive cardiac failure, arrhythmia (not 
controlled by drugs), and right bundle branch block, which were 
treated with a pacemaker, propranolol, and an anticoagulant6.
Recent data from the COVID-19 pandemic have shown that 
the virus can affect the cardiovascular system. The damage due 
to COVID-19 is probably multifactorial, and can result from an 
imbalance between high metabolic demand and low cardiac reserve, 
systemic inflammation, and/or thrombogenesis. Direct cardiac 
damage from the virus also occurs, primarily in patients with 
cardiovascular risk factors or preexisting cardiovascular diseases7.
Although the patient was classified as having borderline leprosy 
and Chagas cardiomyopathy, she did not experience a recrudescence 
of leprosy symptoms, worsening of previous cardiovascular 
manifestations, or a severe case of COVID-19. Although the vast 
majority of patients with COVID-19 have a good clinical outcome, 
we hypothesize that leprosy treatment, due to its immunomodulatory 
properties, could also have protected this patient. Moreover, 
exposure to M. leprae itself, due to its immunogenic similarities 
to M. bovis, could conceivably confer protection against the 
severe manifestations of COVID-19, given that the BCG vaccine 
has already been postulated to possess such properties8. These 
hypotheses are worth testing directly in future studies.
The present patient also developed mucosal manifestations, 
likely related to SARS-CoV-2 infection, as reported elsewhere. 
Initial studies from China reported low frequencies of cutaneous 
manifestations in COVID-19 patients (0.2%), but reports are 
increasing, including acro-ischemia, chilblain-like eruptions, 
petechiae or purpuric rash, chickenpox-like rash, urticaria, erythema 
multiforme, maculopapular rash, mottling, and pityriasis rosea-
like rash8. Ulcerative mucosal lesions, similar to those seen in 
our patient, were also described by Carreras-Presas et al9. These 
mucosal ulcers are common primary lesions observed in other viral 
infections, such as herpes and hand, foot, and mouth disease. It is 
worth noting that our patient had no fever or cough but initially 
presented with mucosal manifestations.
It is important to highlight the hypothesis raised by the scientific 
community that the BCG vaccine may mitigate the effects of 
COVID-19, as it could explain why the patient’s daughter did 
not contract COVID-19 despite being in close contact with her. 
Recent studies have demonstrated an inversely proportional 
relationship between the number of COVID-19 cases in countries 
with widespread BCG vaccine use and the relatively high numbers 
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of COVID-19 cases in countries that have suspended the universal 
administration of the BCG vaccine, such as Italy, Spain, and the 
United States10. Interestingly, in Brazil, the BCG vaccine, in addition 
to being standard for newborns, is also used as prophylaxis for 
leprosy in household contacts. It is possible that a specific sub-
analysis of this particular coinfection could add further information 
about the natural history of COVID-19 and leprosy.
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